M
Madrigal Pharmaceuticals
Biotech & Life Sciences · West Conshohocken, United States · Founded 2011 · IPO 2016
The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease MoreLess
Madrigal Pharmaceuticals is a biopharmaceutical company dedicated to developing novel therapeutics for nonalcoholic steatohepatitis (NASH), a severe liver disease. The company operates in the healthcare and pharmaceutical market, focusing on patients with moderate to advanced liver fibrosis (stages F2 to F3) and those with compensated cirrhosis. Madrigal's business model revolves around research and development, clinical trials, and the commercialization of its therapies. The company's first therapy has received accelerated approval from the U.S. Food and Drug Administration (FDA) and is currently undergoing Phase 3 clinical trials. Madrigal generates revenue through the sale of its FDA-approved treatments and potentially through partnerships and licensing agreements. The company's target clients include healthcare providers, hospitals, and patients suffering from NASH.
Keywords: biopharmaceutical, NASH, liver disease, therapeutics, FDA-approved, clinical trials, fibrosis, cirrhosis, healthcare, pharmaceutical.
Talent graph
Madrigal Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Investors
3 investors on Madrigal Pharmaceuticals's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Madrigal Pharmaceuticals has talent and traffic
team presence
across markets
Patent intelligence
$25M patent portfolio · 42 active families
Where Madrigal Pharmaceuticals concentrates vs peers
Each axis is a top-10 topic across Madrigal Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about Madrigal Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about Madrigal Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Madrigal Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.